Evidence map›Paper›PMID 41084390›Full record

ArticleAmerican journal of epidemiology2026

An alternative method for assessing the fragility of survival analysis results: a proof-of-concept study based on the log-rank test.

Xing Xing, Aiwen Xing, Kannan Natarajan, Haitao Chu, Lifeng Lin, Jiayi Tong

Abstract read
In one paragraph

Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xing XingDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.ORCID 0000-0001-9394-8957
Aiwen XingBiostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.ORCID 0000-0003-4901-7025
Kannan NatarajanStatistical Research and Data Science Center, Pfizer Inc., New York, NY, United States.
Haitao ChuStatistical Research and Data Science Center, Pfizer Inc., New York, NY, United States.ORCID 0000-0003-0932-598X
Lifeng LinDepartment of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, United States.ORCID 0000-0002-3562-9816
Jiayi TongDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.ORCID 0000-0002-1213-6699

Funding

Advanced Methods and Software for Trial Sequential Analysis in Living Systematic ReviewsR21LM014533 · NLM · UNIVERSITY OF ARIZONA · PI LIN, LIFENG · 2024 to 2025
$364k
Innovative Data Integration Models for Handling Evidence Inconsistency in AD/ADRD ResearchR03AG093555 · NIA · UNIVERSITY OF ARIZONA · PI LIN, LIFENG · 2025 to 2025
$301k
NIA NIH HHS R03 AG093555NLM NIH HHS R21 LM014533the Arizona Biomedical Research Centre RFGA2023-008-11
6 · The paper itself

Abstract

Misused P values and an excessive focus on significance have prompted calls for added robustness metrics. The fragility index (FI), which quantifies how many event status changes are needed to reverse statistical significance, serves as a useful complement. Although FI has been applied in various settings such as dose-finding trials and meta-analyses, its use in survival analysis is limited due to complexities like censoring, variable follow-up, and hazard assumptions. Existing FI adaptations for survival data often reassign individuals across intervention arms in randomized controlled trials (RCTs), diverging from FI's original philosophy and reducing clinical plausibility. We propose a modified FI for survival data (FIS) to assess the robustness of survival analysis results in RCTs. Rather than reassigning individuals between intervention and control groups, FIS preserves the foundational principles of the original FI by quantifying the minimum number of changes in outcome status, either events or censoring, needed to overturn statistical significance. To enhance flexibility and practical utility, we extend FIS to assess fragility in both directions: from statistically significant to nonsignificant results and vice versa. We demonstrate the performance of the proposed method through two real-world cases from RCTs.

Indexed as

Randomized Controlled Trials as TopicData Interpretation, StatisticalHumansProof of Concept StudySurvival Analysisfragility indexoncologyrandomized controlled trialssurvival analysis

Identifiers

PMID41084390
PMCPMC12617967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.